|Dr. Sean E. George||Co-Founder, Pres, CEO & Chairman||500k||N/A||1974|
|Mr. Lee Bendekgey||Sec. & COO||425k||N/A||1958|
|Ms. Katherine A. Stueland||Chief Commercial Officer||350k||N/A||1976|
|Ms. Shelly D. Guyer||Chief Financial Officer||N/A||N/A||1960|
|Ms. Laura D'Angelo||Head of Investor Relations||N/A||N/A||N/A|
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. The company also operates AltaVoice, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Invitae Corporation’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 8; Compensation: 9.